[go: up one dir, main page]

DK0956013T3 - Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre - Google Patents

Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre

Info

Publication number
DK0956013T3
DK0956013T3 DK97944022T DK97944022T DK0956013T3 DK 0956013 T3 DK0956013 T3 DK 0956013T3 DK 97944022 T DK97944022 T DK 97944022T DK 97944022 T DK97944022 T DK 97944022T DK 0956013 T3 DK0956013 T3 DK 0956013T3
Authority
DK
Denmark
Prior art keywords
acid
pharmaceutical preparation
preparation containing
stearidonic
containing eicosapentaenoic
Prior art date
Application number
DK97944022T
Other languages
English (en)
Inventor
Frederick Horrobin David
Original Assignee
Scarista Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9621294.9A external-priority patent/GB9621294D0/en
Application filed by Scarista Ltd filed Critical Scarista Ltd
Application granted granted Critical
Publication of DK0956013T3 publication Critical patent/DK0956013T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK97944022T 1996-10-11 1997-10-07 Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre DK0956013T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9621294.9A GB9621294D0 (en) 1996-10-11 1996-10-11 Fatty acid treatment
GBGB9626062.5A GB9626062D0 (en) 1996-10-11 1996-12-16 Fatty acid treatment
PCT/GB1997/002738 WO1998016216A1 (en) 1996-10-11 1997-10-07 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid

Publications (1)

Publication Number Publication Date
DK0956013T3 true DK0956013T3 (da) 2003-08-04

Family

ID=26310221

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97944022T DK0956013T3 (da) 1996-10-11 1997-10-07 Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre

Country Status (24)

Country Link
US (5) US6331568B1 (da)
EP (1) EP0956013B1 (da)
JP (1) JP4151853B2 (da)
KR (2) KR20060061409A (da)
CN (1) CN1109543C (da)
AT (1) ATE236627T1 (da)
AU (1) AU731692C (da)
BR (1) BR9713479A (da)
CA (1) CA2268257C (da)
CZ (1) CZ293704B6 (da)
DE (1) DE69720787T2 (da)
DK (1) DK0956013T3 (da)
ES (1) ES2195175T3 (da)
ID (1) ID21473A (da)
IL (1) IL129367A0 (da)
IS (1) IS2180B (da)
NO (1) NO326926B1 (da)
NZ (1) NZ334852A (da)
PL (1) PL190181B1 (da)
PT (1) PT956013E (da)
SK (1) SK285210B6 (da)
TR (1) TR199900786T2 (da)
TW (1) TW429145B (da)
WO (1) WO1998016216A1 (da)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0956013T3 (da) * 1996-10-11 2003-08-04 Scarista Ltd Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre
JP2002501887A (ja) * 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6107334A (en) 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
FR2788437B1 (fr) * 1999-01-14 2006-08-11 Inst Rech Biolog Sa Nouvelle utilisation de phospholipides d'origine vegetale et animale en therapeutique nutritionnelle
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
AU2006201772B2 (en) * 1999-01-27 2010-02-04 Amarin Neuroscience Limited Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
GB9901809D0 (en) 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
GB9904895D0 (en) * 1999-03-03 1999-04-28 Scarista Limited Regulators of coenzyme-A-independent transacylase as psychotropic drugs
ES2425114T3 (es) * 2000-03-16 2013-10-11 The Mclean Hospital Corporation CDP-colina y uridina para el tratamiento del abuso del acohol
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
WO2002092779A2 (en) * 2001-05-17 2002-11-21 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
DE60221287D1 (de) 2001-11-08 2007-08-30 Atrium Medical Corp Intraluminale vorrichtung mit einer ein therapeutisches-mittel enthaltenden beschichtung
NL1019368C2 (nl) 2001-11-14 2003-05-20 Nutricia Nv Preparaat voor het verbeteren van receptorwerking.
JP2006502213A (ja) 2002-10-10 2006-01-19 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 脂肪族アルコール類の塩基性エステルおよび抗炎症薬または免疫調整薬としての使用
GB0311081D0 (en) * 2003-05-14 2003-06-18 Btg Internat Limted Treatment of neurodegenerative conditions
US7964641B2 (en) * 2003-08-18 2011-06-21 Btg International Limited Treatment of neurodegenerative conditions
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
WO2005086619A2 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
WO2005072306A2 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) * 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
US20050266051A1 (en) * 2004-05-27 2005-12-01 The Procter & Gamble Company Pet food compositions and methods
US20090215714A1 (en) * 2004-06-10 2009-08-27 Perry Renshaw Pyrimidines, such as cytidine, in treatments for patients with biopolar disorder
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
US20060067977A1 (en) * 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20090011116A1 (en) * 2004-09-28 2009-01-08 Atrium Medical Corporation Reducing template with coating receptacle containing a medical device to be coated
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
EP1819297B1 (en) 2004-09-28 2015-01-14 Atrium Medical Corporation Uv cured gel and method of making
US20060083768A1 (en) * 2004-09-28 2006-04-20 Atrium Medical Corporation Method of thickening a coating using a drug
US7550286B2 (en) 2004-11-04 2009-06-23 E. I. Du Pont De Nemours And Company Docosahexaenoic acid producing strains of Yarrowia lipolytica
CN101102988B (zh) * 2004-11-19 2011-12-14 马泰克生物科学公司 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
GB0425932D0 (en) * 2004-11-25 2004-12-29 Btg Int Ltd Structured phospholipids
GB2421909A (en) * 2004-12-23 2006-07-12 Laxdale Ltd Pharmaceutical compositions comprising EPA and methods of use
GB0504362D0 (en) 2005-03-02 2005-04-06 Btg Int Ltd Cytokine modulators
GB0504333D0 (en) * 2005-03-02 2005-04-06 Btg Int Ltd Treatment of cytokine dysregulation
KR20130101596A (ko) * 2005-07-08 2013-09-13 마텍 바이오싸이언스스 코포레이션 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
EP1968567B1 (en) * 2005-12-20 2014-06-18 Cenestra, Llc Omega 3 fatty acid formulations
US20090320148A1 (en) * 2006-01-31 2009-12-24 Martek Biosciences Corporation Oxylipins from stearidonic acid and gamma-linolenic acid and methods of making and using the same
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
WO2008057328A2 (en) 2006-11-06 2008-05-15 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US20100130611A1 (en) * 2006-12-20 2010-05-27 Cenestra Llc Omega 3 fatty acid formulations
WO2008103753A2 (en) * 2007-02-20 2008-08-28 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2008106092A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
US8323935B2 (en) 2007-10-03 2012-12-04 E I Du Pont De Nemours And Company Optimized strains of Yarrowia lipolytica for high eicosapentaenoic acid production
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
EP2211881A4 (en) * 2007-11-01 2012-01-04 Wake Forest University School Of Medicine COMPOSITIONS AND METHOD FOR THE PREVENTION AND TREATMENT OF SEDUCTIVES OF MAMMALS
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
WO2010028067A1 (en) 2008-09-02 2010-03-11 Amarin Corporation Plc Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
WO2010028419A1 (en) * 2008-09-09 2010-03-18 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US8060617B2 (en) * 2008-12-19 2011-11-15 Cisco Technology, Inc. Reserving network resources during scheduling of meeting event
ES2426132T3 (es) 2009-02-10 2013-10-21 Amarin Pharmaceuticals Ireland Limited Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia
GB0904300D0 (en) 2009-03-12 2009-04-22 Amarin Neuroscience Ltd Essential fatty acid compounds
DK2424356T3 (da) 2009-04-29 2017-12-04 Amarin Pharmaceuticals Ie Ltd Stabil farmaceutisk sammensætning og fremgangsmåder til brug af samme
EP4008327A1 (en) 2009-04-29 2022-06-08 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ597193A (en) 2009-06-15 2014-01-31 Amarin Pharmaceuticals Ie Ltd Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
ES2554657T3 (es) 2009-09-23 2015-12-22 Amarin Pharmaceuticals Ireland Limited Composición farmacéutica que comprende ácido graso omega-3 y derivado hidroxi de una estatina y métodos de uso de la misma
US8372465B2 (en) 2010-02-17 2013-02-12 Bunge Oils, Inc. Oil compositions of stearidonic acid
CA2792090C (en) * 2010-03-04 2019-05-14 Amarin Pharma, Inc. Compositions and methods for treating and/or preventing cardiovascular disease
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
WO2012074930A2 (en) 2010-11-29 2012-06-07 Amarin Pharma, Inc. Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
WO2012083034A1 (en) * 2010-12-15 2012-06-21 Louis Sanfilippo Modulation of neurotrophic factors by omega-3 fatty acid formulations
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
EP2540292A1 (en) * 2011-06-28 2013-01-02 Nestec S.A. DHA and EPA in the reduction of oxidative stress
WO2013070735A1 (en) 2011-11-07 2013-05-16 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
NZ737380A (en) 2012-06-29 2019-05-31 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
EP3102227A4 (en) 2014-02-07 2017-09-27 University Of Utah Research Foundation Combination of creatine, an omega-3 fatty acid, and citicoline
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2016063959A1 (ja) * 2014-10-24 2016-04-28 日油株式会社 環状ベンジリデンアセタールリンカーを有する抗体―薬物複合体
ES2607715B1 (es) * 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
CN111991386A (zh) 2018-09-24 2020-11-27 阿马里纳药物爱尔兰有限公司 降低受试者的心血管事件的风险的方法
CN116350616A (zh) 2019-11-12 2023-06-30 阿马里纳药物爱尔兰有限公司 降低心房纤颤和/或心房扑动受试者心血管事件风险的方法
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1239587A (en) 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US5252333A (en) * 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
GB8906369D0 (en) * 1989-03-20 1989-05-04 Tisdale Michael J Eicosapentaenoic acid
CH678181A5 (da) * 1989-05-22 1991-08-15 Nestle Sa
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
ES2059880T3 (es) * 1990-05-23 1994-11-16 Nestle Sa Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.
JP3400466B2 (ja) 1991-10-28 2003-04-28 日本水産株式会社 高純度エイコサペンタエン酸またはそのエステルの製造方法
GB9224809D0 (en) 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9519661D0 (en) * 1995-09-27 1995-11-29 Scotia Holdings Plc Fatty acid treatment
DK0956013T3 (da) * 1996-10-11 2003-08-04 Scarista Ltd Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre
US6791937B2 (en) * 1999-05-21 2004-09-14 Matsushita Electric Industrial Co., Ltd. Recordable optical disk

Also Published As

Publication number Publication date
SK285210B6 (sk) 2006-09-07
KR20000049016A (ko) 2000-07-25
US20030045578A1 (en) 2003-03-06
EP0956013A1 (en) 1999-11-17
TW429145B (en) 2001-04-11
ES2195175T3 (es) 2003-12-01
WO1998016216A1 (en) 1998-04-23
SK44899A3 (en) 2000-08-14
IS2180B (is) 2006-12-15
ID21473A (id) 1999-06-17
NZ334852A (en) 2001-05-25
DE69720787D1 (de) 2003-05-15
PL333423A1 (en) 1999-12-06
NO991635D0 (no) 1999-04-06
NO991635L (no) 1999-06-07
CN1109543C (zh) 2003-05-28
US20040014810A1 (en) 2004-01-22
NO326926B1 (no) 2009-03-16
AU4566797A (en) 1998-05-11
JP4151853B2 (ja) 2008-09-17
KR20060061409A (ko) 2006-06-07
JP2001503743A (ja) 2001-03-21
PT956013E (pt) 2003-08-29
PL190181B1 (pl) 2005-11-30
BR9713479A (pt) 2000-04-11
KR100657642B1 (ko) 2006-12-19
EP0956013B1 (en) 2003-04-09
AU731692B2 (en) 2001-04-05
CA2268257C (en) 2008-05-20
DE69720787T2 (de) 2004-03-18
TR199900786T2 (xx) 1999-07-21
AU731692C (en) 2001-10-11
US20020065319A1 (en) 2002-05-30
US6331568B1 (en) 2001-12-18
US20040048927A1 (en) 2004-03-11
IL129367A0 (en) 2000-02-17
CZ293704B6 (cs) 2004-07-14
HK1020316A1 (en) 2000-04-14
CN1233955A (zh) 1999-11-03
CA2268257A1 (en) 1998-04-23
US6624195B2 (en) 2003-09-23
ATE236627T1 (de) 2003-04-15
IS5017A (is) 1999-03-30
CZ115499A3 (cs) 1999-08-11

Similar Documents

Publication Publication Date Title
DK0956013T3 (da) Farmaceutisk præparat indeholdende eicosapentaensyre og/eller stearidonsyre
NO940277L (no) Triglycerider og blandinger av slike
ATE87825T1 (de) Zusammensetzungen essentieller fettsaeuren.
KR940018091A (ko) 불포화 지방산을 포함하는 처방
DE60000133D1 (de) Essentielle fettsäuren zur vorbeugung von kardiovaskulären anfällen
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
NZ299464A (en) Use of gamma linolenic or dihomogamma linolenic acid in the treatment of Huntington's Chorea
EP0440307A3 (en) Pharmaceutical and dietary composition
FR2754820B1 (fr) Le (-)hydroxycitrate de magnesium, procede de preparation, applications, et compositions notamment pharmaceutiques le renfermant
DE69622722D1 (de) Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselssyndroms
TW336171B (en) Pharmaceutical composition for use in the treatment of vulvar dystrophy and/or vaginal dryness
FI970298A0 (fi) DHA:n käyttö farmaseuttisena koostumuksena
YU89891A (sh) SMEŠE TGF-beta
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
ES2171535T3 (es) Producto nutritivo utilizado en el tratamiento de la colitis ulcerosa y su uso.
AU1821888A (en) Treatment or prevention of memory loss using essential fatty acid compositions
ATE258792T1 (de) Diät mit hohem lipidgehalt
AU554413B2 (en) Linoleic acid and essential fatty acid compositions as
ES2143705T3 (es) Preparaciones cosmeticas y/o farmaceuticas que contienen tensioactivos sacaricos y gliceridos parciales de acidos grasos.
MY129218A (en) Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
KR930012009A (ko) 동맥의 재폐색 방지법
PT89528A (pt) Salicylsaeurehaltiges mittel gegen schuppende hauterkrankungen
TH15810A (th) สูตรผสมที่มีกรดแฟททีชนิดไม่อิ่มตัว